Its Early in 2025 patient and impatient investors ,Anteotech has...

Its Early in 2025 patient and impatient investors ,Anteotech has a few irons in the fire , news on Vidicare's product roll out must be soon ? Vidcare’s planned product roll out in early 2025 , patience for just a bit longer ADO investors .

First commercial evaluation of AnteoBind NXT Targeting first purchase agreement by early 2025 BRISBANE, AUSTRALIA,

AnteoTech Ltd (ASX: ADO) (AnteoTech or the Company) a revenue stage company, providing solutions for the clean energy and life sciences markets using proprietary technologies, is pleased to announce the Company has commenced an evaluation of AnteoBind NXT with Indian biotech, Vidcare Innovations Private Limited (Vidcare), for inclusion in their range of blood diagnostic test products. Key Points
• AnteoBind NXT demonstrated by Vidcare Innovations to improve particle activation being applied to Vidcare’s novel and proprietary in-home test for diagnosis of hypothyroidism
• Vidcare detailed evaluation to confirm AnteoBind NXT provides higher specificity, improved costs and ease of manufacture compared to conventional EDC chemistry
• Hypothyroidism or underactive thyroid is a major health issue if left untreated - prevalent in developing countries
• Vidcare Innovations initiatives are aligned with the Indian Government’s ‘Health for All’ initiative
• Vidcare has agreed to negotiate a supply agreement for AnteoBind NXT if the evaluations are successful – supporting their planned product launch in early 2025

David Radford, Managing Director & Chief Executive Officer of AnteoTech commented: “We are excited by the data we already developed with our AnteoBind NXT product and its applicability to Vidcare’s novel products which shows our superior ability to activate particles for their diagnostic tests over conventional EDC chemistry. We are therefore confident the next stage of detailed evaluation by Vidcare will support this work, by providing their in-home test an important higher specificity in diagnosing hypothyroidism. Once this evaluation is completed, we will then move to execute a purchase agreement so we can support Vidcare’s planned product roll out in early 2025. This is another substantial commercial opportunity for our life sciences division, given the huge medical need to better diagnose underactive thyroids in developing countries, such as India, and through the Indian Government support of Vidcare’s work which is aligned with the initiative “Health for All”. India is a key market for our targeted life sciences approach and this work follows on from our five-year purchase agreement with the Serum Institute of India, signed in late July.”